Abatacept in Giant Cell Arteritis: ABAGART

Purpose: The main purpose of this study is to understand how adults with a new diagnosis of GCA or those with relapsing disease respond to the investigational drug abatacept (also called Orencia). Participants are randomly assigned to receive either abatacept or a placebo. Participants self-administer a weekly subcutaneous injection of abatacept or placebo.

Participants come to the Perelman Center for 8 study visits over 18 months. If during this time, participants do not respond to study treatment or have a relapse, they will have the option to start taking open-label abatacept for 12 months.

ClinicalTrials.gov ID: NCT04474847

Study Duration: 18 to 27 months

Disease(s): Giant Cell Arteritis (GCA)